Enhanced selection of high affinity DNA-reactive B cells following cyclophosphamide treatment in mice

PLoS ONE

Volumn 5, Issue 1, 2010, Pages

  Kawabata, Daisuke ^a   Venkatesh, Jeganathan ^a   Ramanujam, Meera ^a   Davidson, Anne ^a   Grimaldi, Christine M ^a   Diamond, Betty ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; B CELL ACTIVATING FACTOR; CYCLOPHOSPHAMIDE; DEOXYRIBONUCLEASE; DNA ANTIBODY; DNA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; HEAVY CHAIN DISEASE; LYMPHOCYTOPENIA; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; SINGLE DRUG DOSE; SPLEEN CELL; TRANSGENIC MOUSE; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; CYTOLOGY; DRUG EFFECT; IMMUNOLOGY; SERODIAGNOSIS; SPLEEN;

MUS; MUS MUSCULUS;

ANIMALS; B-LYMPHOCYTES; CYCLOPHOSPHAMIDE; DNA; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; NEUTRALIZATION TESTS; SPLEEN;

EID: 77649117940     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008418     Document Type: Article

References (33)

1. Davidson A, Diamond B (2001) Autoimmune diseases. N Engl J Med 345: 340-350.
2. Ray SK, Putterman C, Diamond B (1996) Pathogenic autoantibodies are routinely generated during the response to foreign antigen: a paradigm for autoimmune disease. Proc Natl Acad Sci U S A 93: 2019-2024.
3. Pelanda R, Schwers S, Sonoda E, Torres RM, Nemazee D, et al. (1997) Receptor editing in a transgenic mouse model: site, efficiency, and role in B cell tolerance and antibody diversification. Immunity 7: 765-775.
4. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, et al. (2003) Predominant autoantibody production by early human B cell precursors. Science 301: 1374-1377.
5. Hemendinger RA, Bloom SE (1996) Selective mitomycin C and cyclophosphamide induction of apoptosis in differentiating B lymphocytes compared to T lymphocytes in vivo. Immunopharmacology 35: 71-82.
6. Austin HA 3rd, Patel AD, Cadena CA, Boumpas DT, Balow JE (1997) Ongoing immunologic activity after short courses of pulse cyclophosphamide in the NZB/ W murine model of systemic lupus erythematosus. J Rheumatol 24: 61-68.
7. Looney RJ, Anolik J, Sanz I (2005) Treatment of SLE with anti-CD20 monoclonal antibody. Curr Dir Autoimm 8: 193-205.
8. Eisenberg R, Albert D (2006) B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus. Nat Clin Pract Rheumatol 2: 20-27.
9. Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA (2005) B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology 44: 1542-1545.
10. Ahuja A, Shupe J, Dunn R, Kashgarian M, Kehry MR, et al. (2007) Depletion of B cells in murine lupus: efficacy and resistance. J Immunol 179: 3351-3361.
11. Cambridge G, Isenberg DA, Edwards J, Leandro MJ, Migone TS, et al. (2007) B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis 67: 1011-1016.
12. Boumpas DT, Austin HA 3rd, Fessler BJ, Balow JE, Klippel JH, et al. (1995) Systemic lupus erythematosus: emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Int Med 122: 940-950.
13. Baker D, Karcher K, Antoniou AV, Turk JL, Tan BT, et al. (1987) Changes in lymphocyte subsets after treatment with cyclophosphamide and during the development of contact sensitivity in the guinea pig. Int J Immunopharm 9: 175-183.
14. Offen D, Spatz L, Escowitz H, Factor S, Diamond B (1992) Induction of tolerance to an IgG autoantibody. Proc Natl Acad Sci U S A 89: 8332-8336.
15. Bynoe MS, Grimaldi CM, Diamond B (2000) Estrogen up-regulates Bcl-2 and blocks tolerance induction of naive B cells. Proc Natl Acad Sci USA 97: 2703-2708.
16. Grimaldi CM, Jeganathan V, Diamond B (2006) Hormonal regulation of B cell development: 17 beta-estradiol impairs negative selection of high-affinity DNA-reactive B cells at more than one developmental checkpoint. J Immunol 176: 2703-2710.
17. Venkatesh J, Peeva E, Xu X, Diamond B (2006) Cutting Edge: Hormonal milieu, not antigenic specificity, determines the mature phenotype of autoreactive B cells. J Immunol 176: 3311-3314.
18. Rolink AG, Melchers F (2002) BAFFled B cells survive and thrive: roles of BAFF in B-cell development. Curr Opin Immunol 14: 266-275.
19. Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, et al. (2001) An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 293: 2111-2114.
20. Thompson JS, Bixler SA, Qian F, Vora K, Scott ML, et al. (2001) BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 293: 2108-2111.
21. Batten M, Groom J, Cachero TG, Qian F, Schneider P, et al. (2000) BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 192: 1453-1466.
22. Thien M, Phan TG, Gardam S, Amesbury M, Basten A, et al. (2004) Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20: 785-798.
23. Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, et al. (2007) Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann Rheum Dis 66: 351-357.
24. Ramanujam M, Wang X, Huang W, Liu Z, Schiffer L, et al. (2006) Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 116: 724-734.
25. Macanovic M, Sinicropi D, Shak S, Baughman S, Thiru S, et al. (1996) The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone. Clin Exp Immunol 106: 243-252.
26. Verthelyi D, Dybdal N, Elias KA, Klinman DM (1998) DNAse treatment does not improve the survival of lupus prone (NZB6NZW) F1 mice. Lupus 7: 223-230.
27. Vlachoyiannopoulos PG, Toya SP, Katsifis G, Zintzaras E, Tzioufas AG, et al. (2008) Upregulation of Antiphospholipid Antibodies Following Cyclophosphamide Therapy in Patients with Systemic Lupus Erythematosus. J Rheumatol 35: 1768-1775.
28. Arechiga AF, Habib T, He Y, Zhang X, Zhang AY, et al. (2009) Cutting Edge: The PTPN22 allelic variant associated with autoimmunity impairs B cell signaling. J Immunol 182: 3343-3347.
29. Hondowicz BD, Alexander ST, Quinn WJ 3rd, Pagan AJ, Metzgar MH, et al. (2007) The role of BLyS/BLyS receptors in anti-chromatin B cell regulation. Int Immunol 19: 465-475.
30. Ait-Azzouzene D, Gavin AL, Skog P, Duong B, Nemazee D (2006) Effect of cell:cell competition and BAFF expression on peripheral B cell tolerance and B-1 cell survival in transgenic mice expressing a low level of Igkappa-reactive macroself antigen. Eur J Immunol 36: 985-996.
31. Cyster JG, Hartley SB, Goodnow CC (1994) Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire. Nature 371: 389-395.
32. Doreau A, Belot A, Bastid J, Riche B, Trescol-Biemont MC, et al. (2009) Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 10: 778-785.
33. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, et al. (2005) Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105: 2862-2868.